Log in to save activitiesYour saved activities will show here so that you can easily access them whenever you're ready. Log in hereCME & EducationLog in to keep track of your credits.
Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
The myeloid disorders—including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and the preleukemic disorders myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPNs)—are characterized by a disruption in the normal growth and development of nonlymphocytic blood cells. Along with acute lymphocytic leukemia (ALL), these diseases are collectively diagnosed in over 40,000 people each year in the United States. Research advances in these disorders over the past decade have led to the development of better diagnostic, classification, and risk stratification schemas; new pharmacologic agents and treatment protocols; and, ultimately, improved patient outcomes.
